Compare MobilEye Global Inc (MBLY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs Sana Biotechnology Inc — how do they compare? MobilEye Global Inc trades at $8.87 (market cap $7.54B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: MobilEye Global Inc is far larger — about 6.7× Sana Biotechnology Inc's market cap. Which is the better fit depends on your goals.
| MBLY | SANA | |
|---|---|---|
Market Cap | $7.54B | $1.13B |
Sector | Technology | Health |
52-Week High | $15.54 | $5.92 |
52-Week Low | $6.56 | $2.68 |
Enterprise Value | $6.10B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye (MBLY) trades at $8.80, up 0.57% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat estimates with EPS of $0.19 versus $0.06 expected, driven by an R&D grant, while revenue reached $508 million (Bloomberg, 2026-07-23). The company faces leadership transition as CEO Amnon Shashua steps down after 27 years, amid expanded robotaxi and ADAS initiatives, including a new supply deal with Stellantis (Business Wire, 2026-07-21).
Outlook: Analyst consensus is bullish with a $11.40 price target (61.5% buy ratings), but risks include persistent net losses (-$4.1B in 2026), high EV/EBITDA of 43.25, and execution challenges under new leadership. The stock offers upside if robotaxi adoption accelerates, but profitability concerns and market volatility pose headwinds.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
